These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18936191)

  • 1. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
    Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
    Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.
    Howe AY; Cheng H; Thompson I; Chunduru SK; Herrmann S; O'Connell J; Agarwal A; Chopra R; Del Vecchio AM
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4103-13. PubMed ID: 16940072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
    Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
    Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
    Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
    Tong X; Arasappan A; Bennett F; Chase R; Feld B; Guo Z; Hart A; Madison V; Malcolm B; Pichardo J; Prongay A; Ralston R; Skelton A; Xia E; Zhang R; Njoroge FG
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2365-70. PubMed ID: 20308381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
    Mo H; Lu L; Pilot-Matias T; Pithawalla R; Mondal R; Masse S; Dekhtyar T; Ng T; Koev G; Stoll V; Stewart KD; Pratt J; Donner P; Rockway T; Maring C; Molla A
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4305-14. PubMed ID: 16189112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
    Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
    Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
    Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
    J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
    McCown MF; Rajyaguru S; Le Pogam S; Ali S; Jiang WR; Kang H; Symons J; Cammack N; Najera I
    Antimicrob Agents Chemother; 2008 May; 52(5):1604-12. PubMed ID: 18285474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
    Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of resistance mutations against HCV ketoamide protease inhibitors.
    Tong X; Bogen S; Chase R; Girijavallabhan V; Guo Z; Njoroge FG; Prongay A; Saksena A; Skelton A; Xia E; Ralston R
    Antiviral Res; 2008 Mar; 77(3):177-85. PubMed ID: 18201776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
    Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay.
    Curry S; Qiu P; Tong X
    J Virol Methods; 2008 Nov; 153(2):156-62. PubMed ID: 18755220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
    Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.